Table Of Content00_Angiotensin II.556_pre 7/3/06 4:05 pm Page i
Angiotensin II
Receptor Antagonists
Current Perspectives
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page iii
Angiotensin II
Receptor Antagonists
Current Perspectives
SECOND EDITION
EDITEDBY
GIUSEPPEMANCIAMD
PROFESSORANDCHAIRMAN
DEPARTMENTOFMEDICINE
UNIVERSITYMILANO-BICOCCA
SANGERADOHOSPITAL
MONZA, MILANO
ITALY
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2006 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Version Date: 20130325
International Standard Book Number-13: 978-1-4822-0780-4 (eBook - PDF)
This book contains information obtained from authentic and highly regarded sources. While all reasonable
efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can
accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to
make clear that any views or opinions expressed in this book by individual editors, authors or contributors are
personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guid-
ance contained in this book is intended for use by medical, scientific or health-care professionals and is provided
strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s
medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of
the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be
independently verified. The reader is strongly urged to consult the drug companies’ printed instructions, and
their websites, before administering any of the drugs recommended in this book. This book does not indicate
whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole
responsibility of the medical professional to make his or her own professional judgements, so as to advise and
treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all
material reproduced in this publication and apologize to copyright holders if permission to publish in this form
has not been obtained. If any copyright material has not been acknowledged please write and let us know so we
may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmit-
ted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented,
including photocopying, microfilming, and recording, or in any information storage or retrieval system, without
written permission from the publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.com
(http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Dan-
vers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a
variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of
payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only
for identification and explanation without intent to infringe.
Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com
and the CRC Press Web site at
http://www.crcpress.com
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page v
Contents
List of Contributors vii
Preface xi
1. Angiotensin II antagonists in acute and post-acute
myocardial infarction 1
Gianna Fabbri and Aldo P Maggioni
2. Comparative pharmacology of angiotensin II (AT)
1
receptor antagonists 13
Peter A van Zwieten
3. Stimulation of AT receptors: role in the effect of
2
angiotensin II receptor antagonists 31
Heiko Funke-Kaiser, Ulrike Muscha Steckelings, and
Thomas Unger
4. The use of angiotensin II antagonists in combination
treatment of hypertension 47
Bernard Waeber, François Feihl, and Hans R Brunner
5. Angiotensin II antagonists in the treatment of patients
with renal impairment or failure 69
Luis Miguel Ruilope and Alejandro de la Sierra
6. The antidiabetic effect of angiotensin II receptor
antagonists: evidence, mechanisms, and clinical
significance 85
Theodore W Kurtz
7. Angiotensin II antagonists, diabetes, and metabolic
syndrome 99
Guido Grassi, Fosca Quarti Trevano, and Giuseppe
Mancia
8. Angiotensin II antagonists and protection against
subclinical cardiac and vascular damage 111
Enrico Agabiti-Rosei, Maria Lorenza Muiesan, and
Damiano Rizzoni
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page vi
vi Contents
9. Angiotensin receptor blockers for chronic heart
failure 127
John GF Cleland and Huan Loh
10. Cerebrovascular prevention by angiotensin II receptor
antagonists 173
Massimo Volpe and Giuliano Tocci
11. Past and ongoing trials with angiotensin II
antagonists: data and perspectives regarding the
treatment of hypertension 189
Sverre E Kjeldsen
Index 209
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page vii
Contributors
Enrico Agabiti-Rosei MD
Department of Medical and Surgical Sciences
University of Brescia
Brescia
Italy
Hans R Brunner MD
Division of Clinical Pathophysiology
University Hospital
Lausanne
Switzerland
John GF Cleland MD
Department of Cardiology
University of Hull
Kingston-upon-Hull
UK
Alejandro de la Sierra MD
Hypertension Unit
Hospital Clínic
Barcelona
Spain
Gianna FabbriMD
ANMCO Research Center
Florence
Italy
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page viii
viii Contributors
François Feihl MD Huan Loh MBBS
Division of Clinical Pathophysiology Department of Cardiology
University Hospital University of Hull
Lausanne Kingston-upon-Hull
Switzerland UK
Guido Grassi MD Aldo P Maggioni MD
Department of Clinical Medicine, Prevention ANMCO Research Center
and Applied Biotechnologies Florence
University of Milano-Bicocca Italy
Milan
Italy Giuseppe Mancia MD
Department of Clinical Medicine, Prevention
Heiko Funke-Kaiser MD and Applied Biotechnologies
Center for Cardiovascular Research (CCR) University of Milano-Bicocca
Institute of Pharmacology and Toxicology Milan
Charité – Universitätsmedizin Berlin Italy
Berlin
Germany Maria Lorenza Muiesan MD
Department of Medical and Surgical Sciences
Sverre E Kjeldsen MDPhDFAHA University of Brescia
Chief Physician and Professor Brescia
Department of Cardiology Italy
Ullevaal University Hospital
Oslo Damiano Rizzoni MD
Norway Department of Medical and Surgical Sciences
and University of Brescia
Adjunct Professor Brescia
Division of Cardiovascular Medicine Italy
University of Michigan
Ann Arbor Luis Miguel Ruilope MD
Michigan Hypertension Unit
USA Hospital 12 de Octubre
Madrid
Theodore W Kurtz MD Spain
Professor and Vice Chair
Department of Laboratory Medicine Ulrike Muscha Steckelings MD
University of California Center for Cardiovascular Research (CCR)
San Francisco, California Charité – Universitätsmedizin Berlin
USA Berlin
Germany
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page ix
Contributors ix
Giuliano Tocci MD Peter A van Zwieten MD
Faculty of Medicine Academic Medical Centre
University of Rome University of Amsterdam
Rome Amsterdam
Italy The Netherlands
Fosca Quarti Trevano MD Massimo Volpe MD
Department of Clinical Medicine, Prevention Professor of Cardiology
and Applied Biotechnologies Faculty of Medicine
University of Milano-Bicocca University La Sapienza of Rome
Milan Rome
Italy Italy
Thomas Unger MD Bernard Waeber MD
Center for Cardiovascular Research (CCR) Division of Clinical Pathophysiology
Institute of Pharmacology and Toxicology University Hospital
Charité – Universitätsmedizin Berlin Lausanne
Berlin Switzerland
Germany
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page xi
Preface
Following their introduction into the medical
armamentarium, angiotensin II antagonists have progressively
gained ground and are now essential therapeutic tools, which
are used to treat a variety of diseases. In the world of
evidence-based medicine, this has been made possible by the
design, implementation and completion of a large number of
important studies. These studies have shown that this group
of drugs offer protection against conditions such as
hypertension, heart failure, post-myocardial infarction,
primary and secondary prevention of stroke and prevention or
management of diabetes and its renal complications. An
update on this large new body of information is the aim of
this book, which follows 6 years after the first edition.
During this period pathophysiological and clinical research
has enormously increased the body of evidence on the clinical
use of these drugs. First, angiotensin II antagonists have been
definitively shown to be effective hypertensive agents both
when used alone and when used in combination with several
other drugs. Second, it has been shown that the action of
these drugs offers a large nephroprotective effect in diabetes,
the appearance and progression of renal damage being
effectively delayed by their long-term use. Third, angiotensin
II antagonists oppose the harmful effects of angiotensin II
may offer a special protection against the occurrence or the
recurrence of cerebrovascular disease. All this has been
accompanied by trial evidence indicating that these drugs are
useful therapeutic tools in patients recovering from a
myocardial infarction or those experiencing heart failure both
in the absence or presence of ACE-inhibitors. Finally,
angiotensin II antagonists have been shown to prevent or
00_Angiotensin II.556_pre 7/3/06 4:05 pm Page xii
xii Preface
delay the appearance of diabetes as well as to oppose the progression and favour the regression of
subclinical organ damage. This is a fundamental aspect of future preventive strategies, which aim
to maintain patients at low risk rather than having to intervene when a high risk and thus partly
irreversible condition has already occurred.
This second edition of the book on angiotensin II antagonists, just as the first, is written by
worldwide renowned experts in the pathophysiological and clinical aspects of cardiovascular
disease. I hope its readers will find the book interesting and that it meets its intended goal.
A special word of gratitude is due to our publisher, Alan Burgess and Catriona Dixon,
Production Editor, for their valuable assistance, which made publication possible.
Giuseppe Mancia
